Quick Answer
Artiva Biotherapeutics, Inc. reported Net Income Loss of -$83.87 million for the year ending 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -28.3% in Net Income Loss from 2024 to 2025.
- This data is from Artiva Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$16.72 million | Q2 2023: -$11.28 million | Q3 2023: $11.28 million | Q1 2024: -$13.96 million | Q2 2024: -$17.84 million | Q3 2024: -$17.47 million | Q1 2025: -$20.31 million | Q2 2025: -$21.25 million | Q3 2025: -$21.53 million.
- Over the full 3 years of available data (2023 to 2025), Artiva Biotherapeutics, Inc.'s Net Income Loss has declined by 192.0%.
- Historical annual values: Fiscal year 2025: -$83.87 million | Fiscal year 2024: -$65.37 million | Fiscal year 2023: -$28.72 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: